A randomized, open-label, pragmatic study to assess reliever-triggered inhaled corticosteroid in African American/Black and Hispanic/Latinx adults with asthma: Design and methods of the PREPARE trial.

Journal Article (Journal Article)

Asthma prevalence, morbidity, and mortality disproportionately impact African American/Black (AA/B) and Hispanic/Latinx (H/L) communities. Adherence to daily inhaled corticosteroid (ICS), recommended by asthma guidelines in all but the mildest cases of asthma, is generally poor. As-needed ICS has shown promise as a patient-empowering asthma management strategy, but it has not been rigorously studied in AA/B or H/L patients or in a real-world setting. Design and Aim The PeRson EmPowered Asthma RElief (PREPARE) Study is a randomized, open-label, pragmatic study which aims to assess whether a patient-guided, reliever-triggered ICS strategy called PARTICS (Patient-Activated Reliever-Triggered Inhaled CorticoSteroid) can improve asthma outcomes in AA/B and H/L adult patient populations. In designing and implementing the study, the PREPARE research team has relied heavily on advice from AA/B and H/L Patient Partners and other stakeholders. Methods PREPARE is enrolling 1200 adult participants (600 AA/Bs, 600H/Ls) with asthma. Participants are randomized to PARTICS + Usual Care (intervention) versus Usual Care (control). Following a single in-person enrollment visit, participants complete monthly questionnaires for 15 months. The primary endpoint is annualized asthma exacerbation rate. Secondary endpoints include asthma control; preference-based quality of life; and days lost from work, school, or usual activities. Discussion The PREPARE study features a pragmatic design allowing for the real-world assessment of a patient-centered, reliever-triggered ICS strategy in AA/B and H/L patients. Outcomes of this study have the potential to offer powerful evidence supporting PARTICS as an effective asthma management strategy in patient populations that suffer disproportionately from asthma morbidity and mortality.

Full Text

Duke Authors

Cited Authors

  • Israel, E; Cardet, JC; Carroll, JK; Fuhlbrigge, AL; Pace, WD; Maher, NE; She, L; Rockhold, FW; Fagan, M; Forth, VE; Hernandez, PA; Manning, BK; Rodriguez-Louis, J; Shields, JB; Coyne-Beasley, T; Kaplan, BM; Rand, CS; Morales-Cosme, W; Wechsler, ME; Wisnivesky, JP; White, M; Yawn, BP; McKee, MD; Busse, PJ; Kaelber, DC; Nazario, S; Hernandez, ML; Apter, AJ; Chang, K-L; Pinto-Plata, V; Stranges, PM; Hurley, LP; Trevor, J; Casale, TB; Chupp, G; Riley, IL; Shenoy, K; Pasarica, M; Calderon-Candelario, RA; Tapp, H; Baydur, A

Published Date

  • February 2021

Published In

Volume / Issue

  • 101 /

Start / End Page

  • 106246 -

PubMed ID

  • 33316456

Pubmed Central ID

  • PMC8130188

Electronic International Standard Serial Number (EISSN)

  • 1559-2030

Digital Object Identifier (DOI)

  • 10.1016/j.cct.2020.106246


  • eng

Conference Location

  • United States